



**AUSTRALIA**  
**Biotech**  
**Invest 2016**

Connecting Capital with Innovation

[www.australiabiotechinvest.com.au](http://www.australiabiotechinvest.com.au)

26 - 27  
October  
2016

Host Industry Body Host State Partner Major Partner

AusBiotech  
AUSTRALIA'S BIOTECHNOLOGY ORGANISATION

MELBOURNE  
Victoria  
Australia

100<sup>CS</sup>  
Just getting started

Melbourne Convention  
Centre, Victoria, Australia

## Race Oncology

Race Oncology is a specialty pharma company pursuing later stage assets, value added products and repurposing opportunities, principally in the cancer field. Our first asset is a chemotherapy drug called Bisantrene, which was the subject of more than 40 phase II studies before it was lost in a series of big pharma mergers during the 1990s. We intend to launch Bisantrene during 2017/18 via a named patient program (NPP) in Europe, aimed at salvage therapy in relapsed/refractory Acute Myeloid Leukemia (AML). We are now seeking licensing partners for all countries outside Europe.